

YWHAQ Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP2929a

Specification

YWHAQ Antibody (N-term) Blocking Peptide - Product Information

Primary Accession P27348

YWHAQ Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 10971

Other Names

14-3-3 protein theta, 14-3-3 protein T-cell, 14-3-3 protein tau, Protein HS1, YWHAQ

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP2929a was selected from the N-term region of human YWHAQ. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

YWHAQ Antibody (N-term) Blocking Peptide - Protein Information

Name YWHAQ

Function

YWHAQ Antibody (N-term) Blocking Peptide - Background

YWHAQ belongs to the 14-3-3 family of proteins which mediate signal transduction by binding to phosphoserine-containing proteins. This highly conserved protein family is found in both plants and mammals, and this protein is 99% identical to the mouse and rat orthologs.

YWHAQ Antibody (N-term) Blocking Peptide - References

Kuzelova, K., et.al., J. Cell. Biochem. 106 (4), 673-681 (2009)





Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1.

Cellular Location

Cytoplasm. Note=In neurons, axonally transported to the nerve terminals

Tissue Location

Abundantly expressed in brain, heart and pancreas, and at lower levels in kidney and placenta. Up-regulated in the lumbar spinal cord from patients with sporadic amyotrophic lateral sclerosis (ALS) compared with controls, with highest levels of expression in individuals with predominant lower motor neuron involvement

YWHAQ Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides